ESMO 2019: CARD: Randomized, Open-Label Study of Cabazitaxel vs Abiraterone or Enzalutamide in mCRPC
Barcelona, Spain (UroToday.com) Taxanes (docetaxel, cabazitaxel) and androgen receptor-targeted therapies (ARTs; abiraterone, enzalutamide) are the standard of care in metastatic castration resistant ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Tian Zhang outlines management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant prostate cancer with upfront expectation-setting discussions. Dr. Zhang ...
Kevin Shee analyzes Decipher® GRID whole-transcriptome data in 500 active surveillance patients from UCSF. Cox proportional regression identified Long and Yu signatures predicting upgrade risk beyond ...
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Michael Morris discussing a phase 1 study of ...
(UroToday.com) The 2025 ESMO annual meeting featured a biomarker-based personalization in metastatic prostate cancer session and a presentation by Dr. Alice Bernard-Tessier discussing targeting ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
MEVPRO-3 Trial: Testing EZH2 Inhibition in First-Line Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat ...
Phase III Evaluation of Mevrometostat + Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-1 & MEVPRO-2) A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results